

Patient Name SAMPLEREP,CTCP	Patient ID SA00054224	Age 46	Gender F	Order # SA00054224
Ordering Phys CLIENT,CLIENT				DOB 06/10/1966
Client Order # SA00054224	Account Information			Report Notes
Collected 02/25/2013	C7028846-DLMP Rochester 3050 Superior Drive Rochester, MN 55901			
Printed 02/27/2013 12:55				

Test	Flag	Results	Unit	Reference Value	Perform Site*
Circulating Tumor Cells, Prostate			REPORTED 02/27/2013 12:35		
Specimen		Whole Blood			MCR
Specimen ID		1060919			MCR
Order Date		27 Feb 2013 08:45			MCR
Result					MCR
		Favorable, 2 circulating tumor cells/7.5 mL of blood.			
Interpretation					MCR
		The results of this test are favorable (<5 circulating tumor cells/7.5 mL of blood). These results have been interpreted by a physician.			
		In patients with metastatic prostate cancer, favorable results are predictive of longer progression free survival (PFS).			
		In one prospective study, circulating tumor cells (CTCs) were enumerated in the peripheral blood of 231 patients with castration-resistant prostate cancer (CRPC), before starting chemotherapy and monthly thereafter. Patients were stratified into unfavorable and favorable prognostic groups based on CTC levels of 5 or more, or less than 5 CTCs/7.5 mL, respectively. Patients with unfavorable pretreatment CTC (57%) had shorter overall survival (OS) (median OS, 11.5 versus 21.7 months; Cox hazard ratio, 3.3; P < 0.0001). Unfavorable post-treatment CTC counts also predicted shorter OS at 2 to 5, 6 to 8, 9 to 12, and 13 to 20 weeks (median OS, 6.7-9.5 versus 19.6-20.7 months; Cox hazard ratio, 3.6-6.5; P < 0.0001). CTC counts predicted OS better than PSA decrement algorithms at all time points; area under the receiver operator curve for CTC was 81% to 87% and 58% to 68% for 30% PSA reduction (P = 0.0218). Prognosis for patients with (a) unfavorable baseline CTC who converted to favorable CTC improved (6.8 to 21.3 months); (b) favorable baseline CTC who converted to unfavorable worsened (>26 to 9.3 months). CTCs are an accurate and independent predictor of OS in CRPC.			
		1) de Bono JS et al. Clin Cancer Res. 14:6302-9, 2008.			
Reason for Referral		Assess for Circulating Tumor Cells			MCR
Method		CellSearch (TM) System			MCR
Reviewed By		Angela H Zieman			MCR
Release Date		27 Feb 2013 12:32			MCR

Performing Site Legend on Last Page of Report

Patient Name SAMPLEREP,CTCP	Collection Date and Time 02/25/2013	Report Status Final
Page 1 of 2	>> Continued on Next Page >>	

* Report times for Mayo performed tests are CST/CDT

Patient Name SAMPLEREP,CTCP	Patient ID SA00054224	Age 46	Gender F	Order # SA00054224
Ordering Phys CLIENT,CLIENT				DOB 06/10/1966
Client Order # SA00054224	Account Information			Report Notes
Collected 02/25/2013	C7028846-DLMP Rochester 3050 Superior Drive Rochester, MN 55901			
Printed 02/27/2013 12:55				

Test	Flag	Results	Unit	Reference Value	Perform Site*
------	------	---------	------	-----------------	---------------

>> Accession SA00054224 - Continued From Previous Page <<
>> Do Not Discard <<

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director:
-----	---	---------------

Patient Name SAMPLEREP,CTCP	Collection Date and Time 02/25/2013	Report Status Final
Page 2 of 2		** End of Report **

* Report times for Mayo performed tests are CST/CDT